# AHSCT Combined With CAR-T Cells in the Treatment of Refractory and Relapsed Multiple Myeloma

> **NCT05740891** · PHASE1 · UNKNOWN · sponsor: **Zhejiang University** · enrollment: 50 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** BCMA CAR-T cells injection

## Key facts

- **NCT ID:** NCT05740891
- **Lead sponsor:** Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-03
- **Primary completion:** 2025-03
- **Final completion:** 2025-03
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2023-02-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05740891

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05740891, "AHSCT Combined With CAR-T Cells in the Treatment of Refractory and Relapsed Multiple Myeloma". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05740891. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*